TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22140514
Drug: Internet CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet CBT plus weekly telephone follow‐up
Study: 22140514
Drug: Weekly telephone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly telephone follow‐up only
Study: 15569112
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg intravenously
Study: 9142772
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dosing (SDD) of aminoglycosides
Study: 9142772
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily dosing of aminoglycosides
Study: 1430080
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg TB
Study: 1430080
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg TB
Study: 21689179
Drug: Analgesics used
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics used
Study: 10327526
Drug: Randomization-based tests
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomization-based tests for no treatment effect
Study: 8890801
Drug: Aspirin (medication)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (medication)
Study: 1676361
Drug: Antacids and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids and/or histamine‐2‐receptor antagonists
Study: 1676361
Drug: Stress ulcer
Normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Stress ulcer prophylactic therapy titrated to achieve a gastric pH of 3.5 or greater
Study: 21115191
Drug: 60 Second
Normalized name: 60 Second
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 Second Taste Gel
Study: 21115191
Drug: pH7 Gel
Normalized name: Sodium Fluoride 9.05 mg in 1 g BUCCAL GEL [pH7 Gel Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH7 Gel (neutral fluoride agent)
Study: 19900941
Drug: Single-dose cruciferous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose cruciferous diet in GSTM1-null/GSTT1-null individuals
Study: 19900941
Drug: Double-dose cruciferous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose cruciferous diet in GSTM1-null/GSTT1-null men
Study: 19900941
Drug: Double-dose cruciferous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose cruciferous diet in GSTM1+/GSTT1+ men
Study: 16870070
Drug: Bisoprolol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol plus magnesium (Mg)
Study: 16870070
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no combined study medication)
Study: 12825002
Drug: Thyroid-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid-releasing hormone (TRH)
Study: 10427126
Drug: Radiotherapy (RT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy (RT) combined with transcatheter arterial embolization (TAE) and percutaneous ethanol injection (PEI)
Study: 7943099
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (60 mg/day)
Study: 30575484
Drug: sorafenib (400‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib (400‐mg tablet once daily)
Study: 22402913
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (No Treatment)
Study: 20197017
Drug: Schisandra sphenanthera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schisandra sphenanthera extract (SchE) co-administered with Tacrolimus (Tac) in Group A (same dose of Tac)
Study: 20197017
Drug: Schisandra sphenanthera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schisandra sphenanthera extract (SchE) co-administered with Tacrolimus (Tac) in Group B (lower dose of Tac)
Study: 20197017
Drug: Schisandra sphenanthera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schisandra sphenanthera extract (SchE) co-administered with Tacrolimus (Tac)
Study: 2279542
Drug: alpha interferon
Normalized name: Natural alpha interferon
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha interferon (IFN) therapy (1.8 MU/sm/daily for younger patients, 1.0 MU/daily for older patients) followed by splenectomy
Study: 2279542
Drug: alpha interferon
Normalized name: Natural alpha interferon
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha interferon (IFN) therapy (1.8 MU/sm/daily for younger patients, 1.0 MU/daily for older patients) followed by observation
Study: 7002563
Drug: Prostacyclin (PGI2)
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostacyclin (PGI2) intravenous infusion at doses up to 4 ng/kg per min
Study: 7002563
Drug: Prostacyclin (PGI2)
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostacyclin (PGI2) intravenous infusion at 4 ng/kg per min
Study: 7002563
Drug: Prostacyclin (PGI2)
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostacyclin (PGI2) intravenous infusion
Study: 27182005
Drug: Omarigliptin 5-100
Normalized name: Omarigliptin
DrugBank: Omarigliptin (DB11992)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Omarigliptin 5-100 mg single dose
Study: 27182005
Drug: Omarigliptin 1-50
Normalized name: Omarigliptin
DrugBank: Omarigliptin (DB11992)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Omarigliptin 1-50 mg multiple once-weekly dose
Study: 27182005
Drug: Omarigliptin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omarigliptin (various doses)
Study: 23394494
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) with propofol (group T)
Study: 21105991
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin and cisplatin (MVAC)
Study: 19671802
Drug: Ustekinumab (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (45 mg for patients <100 kg or 90 mg for patients >100 kg, administered subcutaneously; second dose at 4 weeks, then every 8-12 weeks based on response)
Study: 18038253
Drug: PRO 160/120
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO 160/120 (160 mg Sabal fruit extract WS 1473 and 120 mg Urtica root extract WS 1031 per capsule, 2 x 1 capsule/day)
Study: 15506025
Drug: Cerec crowns
Normalized name: ceric oxide
DrugBank: Cerium dioxide (DB18493)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerec crowns with reduced stump preparations
Study: 10861146
Drug: Lidocaine treatment
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine treatment group
Study: 10861146
Drug: Bupivacaine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine treatment group
Study: 9092954
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) at daily target dosages of 200-1,000 mg/day
Study: 23965645
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg co-administered with simvastatin
Study: 23965645
Drug: Optimal simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Optimal simvastatin dose
Study: 20550071
Drug: Automated chest
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated chest percussion therapy (CPT) for 10 minutes
Study: 18600390
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of interferon-alpha (6 million units daily for 2 weeks, then three times weekly) plus lamivudine (100 mg daily) for 24 weeks followed by lamivudine alone for 28 weeks (n = 30)
Study: 18600390
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of interferon-alpha plus lamivudine
Study: 18600390
Drug: Lamivudine monotherapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine monotherapy (n = 34)
Study: 1612948
Drug: Chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen of two cycles of cisplatin, bleomycin, vindesine and mitomycin C (first trial, 100 patients)
Study: 1612948
Drug: Chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen of three cycles of cisplatin, 5‐fluorouracil by continuous infusion and vindesine (second trial, 108 patients)
Study: 1612948
Drug: Both chemotherapy
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both chemotherapy regimens
Study: 6704275
Drug: naloxone 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxone 1.2 mg i.v.
Study: 6704275
Drug: saline 3
Normalized name: CVS Saline 3.0% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline 3 ml (placebo)
Study: 26790207
Drug: Heat-sensitive moxibustion
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-sensitive moxibustion added to FOLFOX chemotherapy regimen
Study: 26790207
Drug: FOLFOX chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX chemotherapy regimen alone (Control)
Study: 21506241
Drug: Peginterferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alfa‐2a (135 μg/week for 4 weeks and then 180 μg/week for 44 weeks) plus ribavirin (initial dose of 400 mg/day escalated to 1200 mg/day)
Study: 21506241
Drug: Observation (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (treatment initiated upon significant HCV recurrence)
Study: 17252706
Drug: Generic glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic glimepiride tablets (6 mg)
Study: 17252706
Drug: Innovator glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Innovator glimepiride tablets (6 mg)
Study: 11744338
Drug: ADN plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADN plus glutamine 0.15 g x kg(‐1) x d(‐1)
Study: 11744338
Drug: ADN plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADN plus glutamine 0.30 g x kg(‐1) x d(‐1)
Study: 8121965
Drug: Carbamazepine; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine; specific dosage and duration not mentioned.
Study: 2547030
Drug: MACC +
Approvals — FDA: no, EMA: no, PMDA: no
Description: MACC + W (methotrexate, doxorubicin, cyclophosphamide, and lomustine plus warfarin)
Study: 30784097
Drug: Fostamatinib 100
Normalized name: fostamatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib 100 to 150 mg BID
Study: 28973174
Drug: Low-dose alteplase
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose alteplase (0.6 mg/kg; 15% as bolus and 85% as infusion over 1 hour)
Study: 28973174
Drug: Standard-dose alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose alteplase (0.9 mg/kg; 10% as bolus and 90% as infusion over 1 hour)
Study: 26169991
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (15 mg/kg before tourniquet deflation)
Study: 26169991
Drug: Intra-articular TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular TXA (2 g via drain after wound closure)
Study: 23948786
Drug: Memantine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (10 mg twice per day)
Study: 16894334
Drug: Escitalopram (ESCIT)
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram (ESCIT) 10-20 mg/day (flexible dose) or 10 mg/day (fixed dose for the first 4 weeks)
Study: 16894334
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestogen therapy (ethinyl estradiol 5 microg/day plus norethindrone acetate 1 mg/day)
Study: 16894334
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestogen therapy (EPT)
Study: 3675696
Drug: Amoxicillin 1500
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 1500 mg/d + Ambroxol 90 mg/d (n = 10)
Study: 3675696
Drug: Amoxicillin 1500
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 1500 mg/d (n = 13)
Study: 29235242
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention for the basic aspects of the diagnosis and treatment of osteoporosis
Study: 27432166
Drug: Metformin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1 g) with lifestyle recommendations
Study: 20335626
Drug: 5-mg zinc
Normalized name: zinc sulfate 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg zinc supplement
Study: 20335626
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low-phytate maize and zinc supplement
Study: 11761012
Drug: No omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No omeprazole treatment
Study: 9250109
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg beta-carotene/d for 4 years
Study: 8214666
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg MCA
Study: 8214666
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg MCA
Study: 8214666
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg MCA
Study: 8214666
Drug: DPD (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPD (0.01 and 0.02 mg/kg)
Study: 25510857
Drug: L-dopa (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (50 mg levodopa and 12.5 mg carbidopa)
Study: 19006463
Drug: Internet-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based therapy (IBT)
Study: 17585666
Drug: Red-hot needle
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Red-hot needle therapy combined with blood-letting puncture and cupping
Study: 17585666
Drug: Halometasone cream
Normalized name: halometasone
DrugBank: Halometasone (DB13728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halometasone cream (control)
Study: 7809761
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy (bed rest, information, analgesics)
Study: 3056084
Drug: Hydrocortisone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (100 mg continuous infusion in 5% glucose over 10 h)
Study: 31246283
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg every 2 weeks until further progression)
Study: 26468007
Drug: Capecitabine plus
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine plus cisplatin (CC)
Study: 16426274
Drug: Chronic daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic daily headache (CDH)
Study: 16426274
Drug: Drug addicts
Normalized name: INVESTIGATIONAL DRUGS FOR SUBSTANCE ADDICTION TREATMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug addicts (DA)
Study: 15533865
Drug: Avasimibe 50
Normalized name: Avasimibe
DrugBank: Avasimibe (DB06442)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avasimibe 50 mg QD
Study: 15533865
Drug: Avasimibe 250
Normalized name: Avasimibe
DrugBank: Avasimibe (DB06442)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avasimibe 250 mg QD
Study: 14644397
Drug: Avasimibe 750
Normalized name: Avasimibe
DrugBank: Avasimibe (DB06442)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avasimibe 750 mg QD
Study: 11375853
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of GA and intraoperative thoracic epidural analgesia (TEA)
Study: 11375853
Drug: Multimodal approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal approach (intraoperative GA and TEA, postoperative patient‐controlled TEA, early oral nutrition, enforced mobilization)
Study: 9466279
Drug: Prednisone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (60 mg p.o. twice a day followed by a 2-month taper)
Study: 25855155
Drug: Ceralifimod 0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceralifimod 0.10 mg
Study: 25855155
Drug: Ceralifimod (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceralifimod (0.05 mg)
Study: 30852478
Drug: Fingolimod (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod (0.5 mg)
Study: 12105160
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NTG) 10 mg/24 hours
Study: 12105160
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NTG) with ascorbate (2.4 g/24 hours)
Study: 10022633
Drug: Long-term NSAID
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term NSAID therapy (Group I)
Study: 10022633
Drug: No NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: No NSAID therapy (Group II)
Study: 8815569
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) certoparin (3,000 IU) combined with dihydroergotamine (DHE) (0.5 mg) subcutaneously once daily
Study: 8815569
Drug: Adjusted-dose unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-dose unfractionated heparin (UFH) subcutaneously every 8 hours
Study: 6339343
Drug: Spironolactone and
Normalized name: Spironolactone and torsemide only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone and 500 mg Na p.d
Study: 6339343
Drug: Spironolactone +
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone + furosemide or Moduretic and 500 mg Na p.d
Study: 6339343
Drug: Concentrated ascites
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated ascites reinfusion and 500 mg Na p.d
Study: 6339343
Drug: Unmodified ascites
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unmodified ascites reinfusion and 500 mg Na p.d
Study: 6339343
Drug: Slow ascites
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow ascites drainage and 500 mg Na p.d
Study: 31450257
Drug: Solution-Focused Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-Focused Group Counseling (SFGC) for 5 sessions of 75 minutes each
Study: 31450257
Drug: Solution-Focused Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-Focused Group Counseling (SFGC)
Study: 23704830
Drug: Danzhijiangtang capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danzhijiangtang capsule (DJC)
Study: 21422407
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Exemestane and Tamoxifen)
Study: 17199134
Drug: Bicalutamide 80
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide 80 mg + LHRH-A
Study: 15003438
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 g liquid paraffin per day)
Study: 15003438
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) (2 g per day)
Study: 11307178
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of antioxidants
Study: 6704272
Drug: Extradural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural morphine
Study: 3986067
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (morphine i.v.)
Study: 27090364
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with Dermatophagoides pteronyssinus (D.pt) extract
Study: 22933427
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (E+P or E‐alone)
Study: 14654605
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (5 mg of elemental zinc as zinc sulfate in vitamin B complex‐based syrup, 1 mL daily)
Study: 14654605
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 mL of vitamin‐based syrup)
Study: 11304647
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intramuscular haloperidol
Study: 1738183
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of isotretinoin daily
Study: 22234716
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and alternative medicine (CAM) users
Study: 20031720
Drug: Small-molecule glycoprotein
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-molecule glycoprotein IIb/IIIa inhibitors (tirofiban or eptifibatide)
Study: 9398932
Drug: L-alpha-acetylmethadol (LAAM)
Normalized name: alpha-tocopherol, L-
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-alpha-acetylmethadol (LAAM)
Study: 1287107
Drug: Desipramine, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine, 50 mg by mouth
Study: 1287107
Drug: Intravenous morphine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine, 0.033 mg/kg
Study: 1287107
Drug: Intravenous morphine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine, 0.10 mg/kg
Study: 3907989
Drug: Pirprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirprofen (400 mg twice daily)
Study: 25012645
Drug: Passive physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive physical therapy (group B)